SCHEMBL193772

SCHEMBL193772

O=c1c(O)cccc2ccc(O)c(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 1.00
ALDH1A1 P00352 4/20 0.63
HPGD P15428 3/20 0.63
HSD17B10 Q99714 3/20 0.63
ALOX15 P16050 2/20 0.63
RECQL P46063 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
CYP3A4 P08684 2/20 0.63
KDM4E B2RXH2 1/20 0.63
INPPL1 O15357 1/20 0.63
NSD2 O96028 1/20 0.63
TP53 P04637 1/20 0.63
POLB P06746 1/20 0.63
GAA P10253 1/20 0.63
MAPT P10636 1/20 0.63
THRB P10828 1/20 0.63
PABPC1 P11940 1/20 0.63
PKM P14618 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17069809 0.82 CDK2 (0.70) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL6349397 0.82 CDK2 (0.69) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL31037125 0.82 CDK2 (0.69) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL7915327 0.80 CDK2 (0.67) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL29419413 0.79 CDK2 (0.66) CDK2ALDH1A1HPGDHSD17B10ALOX15
Purpurogallin SCHEMBL2839450 0.79 CDK2 (0.93) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL14399740 0.78 CDK2 (0.64) CDK2ALDH1A1HPGDHSD17B10ALOX15
Purpurogallin SCHEMBL29481120 0.78 CDK2 (1.00) CDK2ALDH1A1HPGDHSD17B10ALOX15
Purpurogallin SCHEMBL33853 0.78 CDK2 (1.00) CDK2ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL344192 0.74 ALDH1A1 (0.61) CDK2ALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2012500186-A 2012-01-05 JP claimed
US-20110123468-A1 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2011-05-26 US claimed
EP-2296760-A2 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2011-03-23 EP claimed
WO-2009156324-A2 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2009-12-30 WO claimed
US-20240424043-A1 COMPOSITION FOR PREVENTING OR TREATING MUSCLE DISEASE COMPRISING ARALIA ELATA EXTRACT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-12-26 US disclosed
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAGGIES PEARL LLC (US) 2022-04-28 US disclosed
US-20210386709-A1 COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2 US GOV VETERANS AFFAIRS (US) 2021-12-16 US disclosed
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAGGIE'S PEARL, LLC (US) 2021-11-02 US disclosed
US-20210030721-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION PERLARA PBC 2021-02-04 US disclosed
WO-2020040831-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION PERLARA PBC (US) 2020-02-27 WO disclosed
US-9707417-B2 Use of benzotropolone derivatives as UV absorbers and antioxidants and their use in sunscreens and/or cosmetic compositions BASF SE (DE) 2017-07-18 US disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-20110123468-A1 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2011-05-26 US disclosed
EP-2296760-A2 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2011-03-23 EP disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
WO-2009156324-A2 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS BASF SE (DE) 2009-12-30 WO disclosed
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
US-5681604-A PLANT EXTRACTS; GREEN TEA, TANNIC ACID, EPICATECHIN GALLATE, GALLIC ACID CARBOHYDRATE REACTION PRODUCTS DELAWARE, UNIVERSITY OF 1997-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 CDK2 2422/4885ALDH1A1 918/4885HPGD 502/4885
US-20240424043-A1 COMPOSITION FOR PREVENTING OR TREATING MUSCLE DISEASE COMPRISING ARALIA ELATA EXTRACT PYGM, CPT1B, GYS1 CDK2 3555/4885ALDH1A1 2901/4885HPGD 2981/4885
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAN1B1, MAN2B1, GAA CDK2 4210/4885ALDH1A1 1692/4885HPGD 2760/4885
US-20110123468-A1 USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS CBR3, SCO2, CBR1 CDK2 359/4885ALDH1A1 690/4885HPGD 415/4885
US-20210030721-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA CDK2 4210/4885ALDH1A1 1692/4885HPGD 2760/4885
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA CDK2 4210/4885ALDH1A1 1692/4885HPGD 2760/4885
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders CCNK, CDK3, CCNO CDK2 27/4885ALDH1A1 1982/4885HPGD 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.